Treatment data | Overall survival | Progression-free survival | Locoregional control | |||
---|---|---|---|---|---|---|
20 trials, 5144 patients | 26 comparisons, 2070 events | 26 comparisons, 2489 events | 26 comparisons, 915 events | |||
rmstD(t*=10Â years) (m) | Hazard ratio | rmstD(t*=10Â years) (m) | Hazard ratio | rmstD(t*=10Â years) (m) | Hazard ratio | |
P value heterogeneity/inconsistency | 0.28 | 0.39 | 0.47 | 0.57 | 0.50 | 0.66 |
P value heterogeneity | 0.29 | 0.30 | 0.22 | 0.24 | 0.26 | 0.35 |
P value inconsistency | 0.33 | 0.54 | 0.87 | 0.96 | 0.84 | 0.92 |
RT* | ||||||
 P score | 0.14 | 0.15 | 0.03 | 0.04 | 0.03 | 0.03 |
CRT-AC | 11.89 [7.40; 16.83] | 0.65 [0.65; 0.76] | 16.10 [11.70; 20.50] | 0.62 [0.54; 0.71] | 8.76 [5.21; 12.31] | 0.53 [0.41; 0.68] |
 P score | 0.92 | 0.96 | 0.88 | 0.94 | 0.71 | 0.82 |
IC-CRT | 8.71 [0.26; 17.16] | 0.80 [0.62; 1.04] | 16.12 [7.97; 24.27] | 0.68 [0.54; 0.85] | 5.97 [− 1.75; 13.68] | 0.72 [0.51; 1.01] |
 P score | 0.72 | 0.63 | 0.86 | 0.79 | 0.47 | 0.50 |
CRT | 7.67 [2.91; 12.43] | 0.77 [0.63; 0.93] | 10.59 [5.91; 15.26] | 0.77 [0.65; 0.91] | 5.08 [1.49; 8.68] | 0.78 [0.58; 1.05] |
 P score | 0.64 | 0.71 | 0.50 | 0.52 | 0.36 | 0.38 |
IC-RT-AC | 5.64 [− 4.50; 15.79] | 0.87 [0.58; 1.31] | 8.10 [− 1.88; 18.09] | 0.83 [0.58; 1.17] | 12.04 [3.40; 20.67] | 0.47 [0.27; 0.82] |
 P score | 0.51 | 0.45 | 0.39 | 0.39 | 0.86 | 0.87 |
IC-RT | 4.31 [− 2.79; 11.40] | 0.92 [0.74; 1.13] | 11.10 [4.37; 17.80] | 0.79 [0.66; 0.93] | 5.65 [− 1.36; 12.66] | 0.83 [0.64; 1.07] |
 P score | 0.40 | 0.33 | 0.53 | 0.46 | 0.43 | 0.28 |
RT-AC | − 0.70 [− 11.01; 9.61] | 0.96 [0.70; 1.30] | 6.37 [− 4.79; 17.53] | 0.84 [0.63; 1.11] | 8.76 [− 0.74; 18.27] | 0.63 [0.37; 1.06] |
 P score | 0.17 | 0.28 | 0.31 | 0.36 | 0.65 | 0.63 |